Vivos Therapeutics completes acquisition of an 11% fully diluted stake in SOD Sciences and 50% ownership of its pseudohypoxia test, using 12,000 Series C convertible preferred shares with $12 million aggregate stated value and no cash consideration

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.